Резултати

eNauka >  Results >  The Expiry of Humira(R) Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
Title: The Expiry of Humira(R) Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
Authors : Moorkens, Evelien; ...; Novakovic, Tanja; ...; (broj, koautora 43)
Issue Date: 2021
Publication: FRONTIERS IN PHARMACOLOGY
ISSN: 1663-9812 Frontiers in Pharmacology Search Idenfier
Type: Article
Collation: vol. 11
DOI: 10.3389/fphar.2020.591134
WoS-ID: 000612144800001
Scopus-ID: 2-s2.0-85099607758
PMID: 33519450
PMCID: PMC7839249
URI: https://enauka.gov.rs/handle/123456789/797016
Project: KULeuvenKU Leuven
Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL)
Metadata source: (Preuzeto iz Nasi u WoS)
M-category: 
21aM21a

66
SCOPUSTM
34
PubMed CentralTM
20
OpenCitations
61
WEB OF SCIENCETM
Алт метрика
Dimensions
Unpaywall

Резултати на еНаука су заштићени ауторским правима и сва права су задржана, осим ако није другачије назначено.